Jagsonpal Pharmaceuticals Ltd
Intimation for Record date of Buy Back.
BUYBACK
◆ Monitor Closely
LOW RISK
📅 Filed on BSE: 27 Apr 2026, 08:27 PM IST · BSE ID: 2a95392e-0b6a-4994-9706-7c329fd50847
View Original BSE Filing (PDF)
💡
In Simple Terms
The company just announced when it will count which shareholders own shares eligible to sell back to the company under its buyback program.
🤖 AI Summary
- Jagsonpal Pharmaceuticals intimated record date for equity share buyback execution
- Filed 27 April 2026 — confirms Board approval from same date has activated
- Record date determines eligible shareholders for buyback participation and share cancellation
- Follows March 2026 buyback announcement; execution phase now formally commenced
🔢 Key Numbers — exact figures from BSE filing, not rounded
Filing Date
27 April 2026
Event
Record Date Intimation for Buyback
🏢 How This Affects the Company
Buyback reduces equity capital and share count on balance sheet. Impacts EPS calculation post-buyback completion; cash deployed from reserves or borrowings.
Execution depends on market conditions and shareholder participation. Delays or low uptake could extend timeline; cash deployment may constrain liquidity if funded from operations.
👥 What This Means For Shareholders
✅
Action Required
Shareholders must ensure shares are held in demat form on or before record date to be eligible for buyback participation.
👤
Who Is Affected
All registered shareholders as of record date are eligible to tender shares. Post-buyback, remaining shareholders' proportional ownership increases due to share count reduction.
🔍
Management Signal
Buyback signals Board confidence in valuation and intent to return capital. Demonstrates proactive capital structure optimization.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Buyback terms disclosure — expect quantum, price cap, and closure date within 7 days
Record date announcement — confirm exact date in stock exchange notice to shareholders
Completion filing — Reg 31A(10) disclosure when buyback settlement concludes
LOW RISK
Record date intimation is routine procedural milestone. Real risks emerge only if execution faces delays, liquidity pressure, or low shareholder uptake.
💡 Investor Takeaway
Record date has been set, confirming Jagsonpal's buyback is now in execution phase. Shareholders eligible on record date will be able to participate. Specific buyback quantum, price range, and completion date remain undisclosed — seek those details in separate Board communication or stock exchange filings.
⚖️ Strengths & Concerns
✅ Positives
- Board approval obtained and record date formally intimated — buyback execution now legally activated and trackable.
- Buyback signals management confidence in intrinsic value and commitment to capital optimization.
⚠️ Concerns
- Filing does not disclose buyback quantum, price cap, or completion deadline — shareholder visibility on scale remains limited.
- No disclosure of funding source or impact on debt ratios — financial structure implications unclear.
📅 Company Track Record
Jagsonpal announced buyback in March 2026, followed by Board approval on 27 April 2026. This record date intimation confirms execution has commenced. No prior buyback history or financial metrics disclosed in available filings.
Based on publicly available historical data. For context only.